INIBO, a Korean botulinum-toxin product in which Huaxi Bio has a strategic stake, received approval from the National Medical Products Administration; Huaxi is the exclusive mainland China partner. The arrangement combines strategic investment and market cooperation to broaden Huaxi’s medical-aesthetics product coverage, diversify its business mix and support long-term development. This extends a prior exclusive-agency collaboration with Korea’s INIBIO for a facial-rejuvenation injection.

2026-10-30

INIBO, a Korean botulinum-toxin product in which Huaxi Bio has a strategic stake, received approval from the National Medical Products Administration; Huaxi is the exclusive mainland China partner. The arrangement combines strategic investment and market cooperation to broaden Huaxi’s medical-aesthetics product coverage, diversify its business mix and support long-term development. This extends a prior exclusive-agency collaboration with Korea’s INIBIO for a facial-rejuvenation injection.